Zacks Research Issues Positive Forecast for Glaukos Earnings

Glaukos Co. (NYSE:GKOS - Free Report) - Investment analysts at Zacks Research increased their FY2024 earnings estimates for shares of Glaukos in a research note issued to investors on Monday, November 25th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings per share of ($1.98) for the year, up from their previous forecast of ($2.32). The consensus estimate for Glaukos' current full-year earnings is ($1.96) per share. Zacks Research also issued estimates for Glaukos' Q4 2024 earnings at ($0.48) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.22) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.23) EPS.

GKOS has been the subject of several other reports. Wells Fargo & Company raised their price objective on shares of Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. StockNews.com raised shares of Glaukos from a "sell" rating to a "hold" rating in a report on Monday, October 21st. Stifel Nicolaus raised their price target on shares of Glaukos from $130.00 to $145.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Needham & Company LLC raised their price target on shares of Glaukos from $131.00 to $137.00 and gave the company a "buy" rating in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. raised their price target on shares of Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $135.45.

Glaukos Stock Performance

GKOS traded up $1.96 on Thursday, hitting $142.69. The company's stock had a trading volume of 348,991 shares, compared to its average volume of 571,878. The company's 50 day simple moving average is $133.56 and its 200-day simple moving average is $124.39. The firm has a market cap of $7.87 billion, a P/E ratio of -47.25 and a beta of 1.02. Glaukos has a 12 month low of $59.58 and a 12 month high of $146.86. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. Glaukos's revenue for the quarter was up 23.9% on a year-over-year basis. During the same period last year, the firm earned ($0.50) EPS.

Insider Transactions at Glaukos

In related news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the transaction, the director now owns 32,336 shares in the company, valued at $4,225,345.12. This trade represents a 8.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 2,275 shares of the business's stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares in the company, valued at $14,198,425.93. The trade was a 2.18 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Glaukos

A number of hedge funds have recently modified their holdings of GKOS. O Shaughnessy Asset Management LLC purchased a new position in shares of Glaukos in the first quarter valued at about $294,000. Cetera Advisors LLC purchased a new position in shares of Glaukos during the first quarter valued at about $213,000. Opaleye Management Inc. purchased a new position in shares of Glaukos during the first quarter valued at about $809,000. GAMMA Investing LLC increased its position in shares of Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock valued at $141,000 after buying an additional 486 shares during the period. Finally, LVW Advisors LLC purchased a new position in shares of Glaukos during the second quarter valued at about $213,000. Hedge funds and other institutional investors own 99.04% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.